Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck signs sale agreement with Santen for Merck's Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific


Tuesday, 13 May 2014 02:15am EDT 

Merck & Co Inc:Signs agreement for Santen Pharmaceutical Co., Ltd. (Santen) to purchase Merck's ophthalmology products.To divest ophthalmics business is part of ongoing strategy to sharpen commercial focus and improve operational effectiveness.Santen will make an upfront payment of about $600 mln and additional payments based on defined sales milestones as needed.Agreement is expected to close in most markets in a few months. 

Company Quote

60.49
-0.15 -0.25%
5 May 2015